Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evalu...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2019
|
| _version_ | 1797056483563667456 |
|---|---|
| author | Ross, LL Walker, AS Lou, Y Tenorio, AR Gibb, DM Double, J Gilks, C McCoig, CC Munderi, P Musoro, G Kityo, CM Grosskurth, H Hakim, J Mugyenyi, PN Cutrell, A Perger, T Shaefer, MS |
| author_facet | Ross, LL Walker, AS Lou, Y Tenorio, AR Gibb, DM Double, J Gilks, C McCoig, CC Munderi, P Musoro, G Kityo, CM Grosskurth, H Hakim, J Mugyenyi, PN Cutrell, A Perger, T Shaefer, MS |
| author_sort | Ross, LL |
| collection | OXFORD |
| description | A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evaluate the safety of initiating standard lamivudine dosing in patients with impaired creatinine clearance (CLcr). Safety data collected through 96 weeks were analyzed after stratification by baseline CLcr (estimated using Cockcroft-Gault) of 30–49 mL/min (n = 168) versus ≥50 mL/min (n = 3,132) and treatment regimen. The Grade 3–4 adverse events (AEs) and serious AEs (for hematological, hepatic and gastrointestinal events), maximal toxicities for liver enzymes, serum creatinine and bilirubin and maximum treatment-emergent hematology toxicities were comparable for groups with baseline CLcr 30–49 versus CLcr≥50 mL/min. No new risks or trends were identified from this dataset. Substantial and similar increases in the mean creatinine clearance (>25 mL/min) were observed from baseline though Week 96 among participants who entered the trial with CLcr 30–49 mL/min, while no increase or smaller median changes in creatinine clearance (<7 mL/min) were observed for participants who entered the trial with CLcr ≥50 mL/min. Substantial increases (> 150 cells/ mm3) in mean CD4+ cells counts from baseline to Week 96 were also observed for participants who entered the trial with CLcr 30–49 mL/min and those with baseline CLcr ≥50 mL/min. Though these results are descriptive, they suggest that HIV-positive patients with CLcr of 30–49 mL/min would have similar AE risks in comparison to patients with CLcr ≥50 mL/min when initiating antiretroviral therapy delivering doses of 300 mg of lamivudine daily through 96 weeks of treatment. Overall improvements in CLcr were observed for patients with baseline CLcr 30–49 mL/min. |
| first_indexed | 2024-03-06T19:23:23Z |
| format | Journal article |
| id | oxford-uuid:1ae2d9ca-41eb-4286-ae62-b77a4324c37f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:23:23Z |
| publishDate | 2019 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:1ae2d9ca-41eb-4286-ae62-b77a4324c37f2022-03-26T10:57:17ZChanges over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/minJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1ae2d9ca-41eb-4286-ae62-b77a4324c37fEnglishSymplectic Elements at OxfordPublic Library of Science2019Ross, LLWalker, ASLou, YTenorio, ARGibb, DMDouble, JGilks, CMcCoig, CCMunderi, PMusoro, GKityo, CMGrosskurth, HHakim, JMugyenyi, PNCutrell, APerger, TShaefer, MSA retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or nevirapine was conducted to evaluate the safety of initiating standard lamivudine dosing in patients with impaired creatinine clearance (CLcr). Safety data collected through 96 weeks were analyzed after stratification by baseline CLcr (estimated using Cockcroft-Gault) of 30–49 mL/min (n = 168) versus ≥50 mL/min (n = 3,132) and treatment regimen. The Grade 3–4 adverse events (AEs) and serious AEs (for hematological, hepatic and gastrointestinal events), maximal toxicities for liver enzymes, serum creatinine and bilirubin and maximum treatment-emergent hematology toxicities were comparable for groups with baseline CLcr 30–49 versus CLcr≥50 mL/min. No new risks or trends were identified from this dataset. Substantial and similar increases in the mean creatinine clearance (>25 mL/min) were observed from baseline though Week 96 among participants who entered the trial with CLcr 30–49 mL/min, while no increase or smaller median changes in creatinine clearance (<7 mL/min) were observed for participants who entered the trial with CLcr ≥50 mL/min. Substantial increases (> 150 cells/ mm3) in mean CD4+ cells counts from baseline to Week 96 were also observed for participants who entered the trial with CLcr 30–49 mL/min and those with baseline CLcr ≥50 mL/min. Though these results are descriptive, they suggest that HIV-positive patients with CLcr of 30–49 mL/min would have similar AE risks in comparison to patients with CLcr ≥50 mL/min when initiating antiretroviral therapy delivering doses of 300 mg of lamivudine daily through 96 weeks of treatment. Overall improvements in CLcr were observed for patients with baseline CLcr 30–49 mL/min. |
| spellingShingle | Ross, LL Walker, AS Lou, Y Tenorio, AR Gibb, DM Double, J Gilks, C McCoig, CC Munderi, P Musoro, G Kityo, CM Grosskurth, H Hakim, J Mugyenyi, PN Cutrell, A Perger, T Shaefer, MS Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min |
| title | Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min |
| title_full | Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min |
| title_fullStr | Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min |
| title_full_unstemmed | Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min |
| title_short | Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min |
| title_sort | changes over time in creatinine clearance and comparison of emergent adverse events for hiv positive adults receiving standard doses 300 mg day of lamivudine containing antiretroviral therapy with baseline creatinine clearance of 30 49 vs ≥50 ml min |
| work_keys_str_mv | AT rossll changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT walkeras changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT louy changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT tenorioar changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT gibbdm changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT doublej changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT gilksc changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT mccoigcc changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT munderip changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT musorog changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT kityocm changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT grosskurthh changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT hakimj changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT mugyenyipn changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT cutrella changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT pergert changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin AT shaeferms changesovertimeincreatinineclearanceandcomparisonofemergentadverseeventsforhivpositiveadultsreceivingstandarddoses300mgdayoflamivudinecontainingantiretroviraltherapywithbaselinecreatinineclearanceof3049vs50mlmin |